Coelho succeeds Lankry as Gamida CFO
Plus: Sullivan becomes chief strategy officer at BioAge, and updates from Athira, Ambrx and FNIH
Cell therapy company Gamida Cell Ltd. (NASDAQ:GMDA) hired Terry Coelho to succeed Shai Lankry as CFO, a planned leadership change that it said coincides with its transition into a commercial-stage company. Coelho was EVP, CFO and chief business development officer at CinCor Pharma Inc., where she led its IPO and a follow-on financing. AstraZeneca plc (LSE:AZN; NASDAQ:AZN acquired CinCor this year. Lankry, who served as CFO for five years, will leave the company on June 2.
BioAge Labs Inc. promoted BJ Sullivan from chief of staff and VP, strategy and business operations to chief strategy officer, a new position at the company. BioAge is developing therapies targeting molecular causes of aging...